2. Poulsen ML, Budtz-Jorgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (vHL). Clin Genet. 2010;77(1):49–59. 10.1111/j.1399-0004.2009.01281.x

3. Nielsen SM, Rhodes L, Blanco I, et al. Von Hippel-Lindau disease: Genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34(18):2172–81. 10.1200/JCO.2015.65.6140

4. Redlich A, Pamporaki C, Lessel L, Fruhwald MC, Vorwerk P, Kuhlen M. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children. Pediatr Blood Cancer. 2021;68(7):e28981. 10.1002/pbc.28981

5. Feletti A, Anglani M, Scarpa B, et al. Von Hippel-Lindau disease: An evaluation of natural history and functional disability. Neuro Oncol. 2016;18(7):1011–20. 10.1093/neuonc/nov313

6. Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77(283):1151–63. 10.1093/qjmed/77.2.1151

7. Binderup ML, Jensen AM, Budtz-Jorgensen E, Bisgaard ML. Survival and causes of death in patients with von Hippel-Lindau disease. J Med Genet. 2017;54(1):11–8. 10.1136/jmedgenet-2016-104058

8. Prasad R, Johnston LB, Savage MO, Martin L, Perry LA, Storr HL. Pediatric endocrine screening for von Hippel-Lindau disease: Benefits and the challenge of compliance. J Endocrinol Invest. 2011;34(4):296–9. 10.1007/BF03347089

9. Priesemann M, Davies KM, Perry LA, et al. Benefits of screening in von Hippel-Lindau disease—Comparison of morbidity associated with initial tumours in affected parents and children. Horm Res. 2006;66(1):1–5. 10.1159/000093008

10. Binderup ML, Bisgaard ML, Harbud V, et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J. 2013;60(12):B4763.

11. Hes FJ, van der Luijt RB, Lips CJ. Clinical management of von Hippel-Lindau (VHL) disease. Neth J Med. 2001;59(5):225–34. 10.1016/S0300-2977(01)00165-6

12. Kruizinga RC, Sluiter WJ, de Vries EG, et al. Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. Endocr Relat Cancer. 2014;21(1):63–71. 10.1530/ERC-13-0308

13. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(12):e68–75. 10.1158/1078-0432.CCR-17-0547

14. Klingler JH, Glasker S, Bausch B, et al. Hemangioblastoma and von Hippel-Lindau disease: Genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020;36(10):2537–52. 10.1007/s00381-020-04712-5

15. Daniels AB, Tirosh A, Huntoon K, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023;129(19):2927–40. 10.1002/cncr.34896

16. Neumann HP, Young WF, Jr., Krauss T, et al. 65 Years of the double helix: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocr Relat Cancer. 2018;25(8):T201–19. 10.1530/ERC-18-0085

17. Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019;285(2):187–204. 10.1111/joim.12869

18. Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: Not a needle in a haystack. Endocr Connect. 2021;10(11):R293–304. 10.1530/EC-21-0294

19. Bechmann N, Moskopp ML, Ullrich M, et al. HIF2alpha supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocr Relat Cancer. 2020;27(11):625–40. 10.1530/ERC-20-0205

20. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. 10.1210/jc.2014-1498

21. Alliance V. The VHL handbook. 5th ed. Boston, MA: VHL Alliance; 2015.

22. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82–94. 10.3171/jns.2003.98.1.0082

23. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol. 1999;117(3):371–8. 10.1001/archopht.117.3.371

24. Reich M, Jaegle S, Neumann-Haefelin E, et al. Genotype-phenotype correlation in von Hippel-Lindau disease. Acta Ophthalmol. 2021;99(8):e1492–1500. 10.1111/aos.14843

25. Lonser RR, Glenn GM, Walther M, et al. Von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67. 10.1016/S0140-6736(03)13643-4

26. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat. 1995;5(1):66–75. 10.1002/humu.1380050109

27. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med. 1998;243(6):541–5. 10.1046/j.1365-2796.1998.00336.x

28. Brauch H, Kishida T, Glavac D, et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect. Hum Genet. 1995;95(5):551–6. 10.1007/BF00223868

29. Fagundes GFC, Petenuci J, Lourenco DM, Jr., et al. New insights into pheochromocytoma surveillance of young patients with VHL missense mutations. J Endocr Soc. 2019;3(9):1682–92. 10.1210/js.2019-00225

30. Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–37. 10.1002/humu.21219